CLINICOPATHOLOGICAL, MOLECULAR SUBTYPE, AND SOMATIC MUTATION PROFILING OF BREAST CANCER SURVIVAL OUTCOMES
Abstract
Breast cancer survival is influenced by complex interactions among clinicopathological characteristics, molecular subtype, and somatic mutation patterns. This study aimed to evaluate the relationship of clinical features, molecular subtype distribution, and selected somatic mutations with survival outcomes in breast cancer patients. A quantitative retrospective observational design was adopted using de-identified breast cancer patient records. The analysis included 1,904 cases with clinicopathological variables, receptor status, molecular subtype classification, somatic mutation profiles, and survival data. Descriptive statistics, frequency distributions, cross-tabulations, independent-samples t-tests,
and chi-square tests were used for analysis. The cohort included 801 living patients and 1,103 deceased patients. Deceased patients had significantly higher age at diagnosis, tumor size, lymph-node positivity, mutation count, and Nottingham Prognostic Index than living patients. Tumor stage and histologic grade showed significant survival-related differences. Molecular subtype was also significantly associated with survival status, with LumA being the most frequent subtype and claudin-low showing the highest living proportion. Somatic mutation profiling identified PIK3CA and TP53 as the most frequent mutations. TP53, MUC16, KMT2C, and GATA3 mutation status showed significant associations with survival outcome. Subtype-specific mutation patterns indicated high TP53 mutation frequency in basal and HER2 tumors and high PIK3CA mutation frequency in LumA tumors. These findings support the value of integrated clinicopathological, molecular subtype, and somatic mutation profiling for understanding breast cancer survival outcomes.
Downloads
References
Alharbi, R. (2020). Breast Cancer Gene Expression Profiles (METABRIC) [Data set]. Kaggle.
https://www.kaggle.com/datasets/raghadalharbi/breast-cancer-gene-expression-profiles-metabric
Chen, T. W. W., Hsiao, W., Dai, M. S., Lin, C. H., Chang, D. Y., Chen, I. C., ... & Lu, Y. S. (2023). Plasma cell-free
tumor DNA, PIK3CA and TP53 mutations predicted inferior endocrine-based treatment outcome in endocrine
receptor-positive metastatic breast cancer. Breast Cancer Research and Treatment, 201(3), 377-385.
Fallahpour, S., Navaneelan, T., De, P., & Borgo, A. (2017). Breast cancer survival by molecular subtype: a populationbased analysis of cancer registry data. Canadian Medical Association Open Access Journal, 5(3), E734-E739.
Guo, Y., Yu, P., Liu, Z., Maimaiti, Y., Chen, C., Zhang, Y., ... & Huang, T. (2017). Prognostic and clinicopathological
value of GATA binding protein 3 in breast cancer: a systematic review and meta-analysis. PloS one, 12(4), e0174843.
Han, Y., Wang, J., & Xu, B. (2020). Clinicopathological characteristics and prognosis of breast cancer with special
histological types: a surveillance, epidemiology, and end results database analysis. The Breast, 54, 114-120.
Howlader, N., Cronin, K. A., Kurian, A. W., & Andridge, R. (2018). Differences in breast cancer survival by molecular
subtypes in the United States. Cancer Epidemiology, Biomarkers & Prevention, 27(6), 619-626.
Jaber, M. I., Song, B., Taylor, C., Vaske, C. J., Benz, S. C., Rabizadeh, S., ... & Szeto, C. W. (2020). A deep learning
image-based intrinsic molecular subtype classifier of breast tumors reveals tumor heterogeneity that may affect
survival. Breast Cancer Research, 22(1), 12.
Jia, M., Liao, N., Chen, B., Zhang, G., Wang, Y., Li, X., ... & Balch, C. M. (2021). PIK3CA somatic alterations in
invasive breast cancers: different spectrum from Caucasians to Chinese detected by next generation
sequencing. Breast Cancer, 28(3), 644-652.
Jørgensen, C. L. T., Larsson, A. M., Forsare, C., Aaltonen, K., Jansson, S., Bradshaw, R., ... & Ryden, L. (2021).
PAM50 intrinsic subtype profiles in primary and metastatic breast cancer show a significant shift toward more
aggressive subtypes with prognostic implications. Cancers, 13(7), 1592.
Kumar, N., Gann, P. H., McGregor, S. M., & Sethi, A. (2023). Quantification of subtype purity in Luminal A breast
cancer predicts clinical characteristics and survival. Breast Cancer Research and Treatment, 200(2), 225-235.
Lu, B., Natarajan, E., Balaji Raghavendran, H. R., & Markandan, U. D. (2023). Molecular classification, treatment,
and genetic biomarkers in triple-negative breast cancer: a review. Technology in cancer research & treatment, 22,
Mei, J., Zhao, J., & Fu, Y. (2020). Molecular classification of breast cancer using the mRNA expression profiles of
immune-related genes. Scientific Reports, 10(1), 4800.
Ochoa, S., de Anda-Jauregui, G., & Hernández-Lemus, E. (2020). Multi-omic regulation of the pam50 gene signature
in breast cancer molecular subtypes. Frontiers in oncology, 10, 845.
Park, J. H., Kwon, M. J., Seo, J., Kim, H. Y., Min, S. K., & Kim, L. S. (2022). Somatic mutations of TP53 identified
by targeted next-generation sequencing are poor prognostic factors for primary operable breast cancer: a single-center
study. Journal of Breast Cancer, 25(5), 379.
Pereira, B., Chin, S. F., Rueda, O. M., Vollan, H. K. M., Provenzano, E., Bardwell, H. A., ... & Caldas, C. (2016). The
somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes. Nature
communications, 7(1), 11479.
Picornell, A. C., Echavarria, I., Alvarez, E., López-Tarruella, S., Jerez, Y., Hoadley, K., ... & Martin, M. (2019). Breast
cancer PAM50 signature: correlation and concordance between RNA-Seq and digital multiplexed gene expression
technologies in a triple negative breast cancer series. BMC genomics, 20(1), 452.
Raj-Kumar, P. K., Liu, J., Hooke, J. A., Kovatich, A. J., Kvecher, L., Shriver, C. D., & Hu, H. (2019). PCA-PAM50
improves consistency between breast cancer intrinsic and clinical subtyping reclassifying a subset of luminal A tumors
as luminal B. Scientific reports, 9(1), 7956.
Xu, H., & Xu, B. (2023). Breast cancer: Epidemiology, risk factors and screening. Chinese journal of cancer
research, 35(6), 565.
Yu, Z., Wang, Z., Yu, X., & Zhang, Z. (2020). RNA‐Seq‐Based Breast Cancer Subtypes Cl
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 International Journal For Research In Biology & Pharmacy
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
In consideration of the journal, Green Publication taking action in reviewing and editing our manuscript, the authors undersigned hereby transfer, assign, or otherwise convey all copyright ownership to the Editorial Office of the Green Publication in the event that such work is published in the journal. Such conveyance covers any product that may derive from the published journal, whether print or electronic. Green Publication shall have the right to register copyright to the Article in its name as claimant, whether separately
or as part of the journal issue or other medium in which the Article is included.
By signing this Agreement, the author(s), and in the case of a Work Made For Hire, the employer, jointly and severally represent and warrant that the Article is original with the author(s) and does not infringe any copyright or violate any other right of any third parties, and that the Article has not been published elsewhere, and is not being considered for publication elsewhere in any form, except as provided herein. Each author’s signature should appear below. The signing author(s) (and, in
